Guselkumab achieves 88.8% IGA 0/1 at week 16 in Chinese patients with plaque psoriasis
Trial shows guselkumab helps Chinese patients with plaque psoriasis
This Phase 4 randomized controlled trial of 327 Chinese patients with moderate-to-severe plaque psoriasis found guselkumab significantly sup…
A new trial shows that guselkumab significantly improves skin clarity for Chinese patients living with moderate to severe plaque psoriasis.
Vunakizumab may induce severe ulcerative colitis and hepatic enzyme elevation in patients with psoriatic arthritis
Vunakizumab Linked to Severe Ulcerative Colitis in Single Case
This case report and literature review describes a single case of severe ulcerative colitis and hepatic enzyme elevation following vunakizum…
A single case report shows a patient developed severe ulcerative colitis and high liver enzymes after receiving vunakizumab injections.
Guselkumab improves ACR20 rates to 58.6% and 62.2% in patients with psoriatic arthritis
Trial shows guselkumab helps adults with psoriatic arthritis
This Phase 3b randomized controlled trial evaluated guselkumab in 451 adults with active psoriatic arthritis who had an inadequate response …
A new trial shows that guselkumab significantly improves symptoms for adults with psoriatic arthritis who did not respond well to previous t…
Guselkumab, Secukinumab, and Brodalumab rank highly for PASI 75 and PASI 90 in plaque psoriasis
New data ranks different treatments for moderate to severe psoriasis
This systematic review and network meta-analysis of 27 RCTs evaluated IL-23/IL-17 inhibitors for moderate-to-severe plaque psoriasis. Guselk…
Comparing several types of biologics helps patients with plaque psoriasis find which medications rank highest for clearing skin and improvin…
IL-17 inhibitors rank highly for clearance of scalp, nail, and palmoplantar psoriasis
Biologics Show Different Success Rates for Scalp and Nail Psoriasis
This network meta-analysis of 5,946 patients evaluated IL-17/IL-23 axis biologics for difficult-to-treat psoriasis sites. The analysis found…
Different biologics show varying success rates for clearing psoriasis on the scalp, nails, and palms based on a large network analysis.
Guselkumab Phase III trials validate 3VAS and 4VAS measures for psoriatic arthritis disease activity assessment
Study checks how well pain scores track joint damage in psoriatic arthritis patients
Phase III randomized clinical trials in 1,405 participants with psoriatic arthritis evaluated guselkumab treatment through week 100.
Pain scores for psoriatic arthritis strongly predict long-term joint damage, giving doctors clear numbers to track real progress and adjust …
Guselkumab showed improved clinical remission in refractory ulcerative colitis versus placebo
Guselkumab shows promise for ulcerative colitis in this early phase 3 trial
This phase 3 randomized trial evaluated guselkumab in adults with moderately to severely active ulcerative colitis who had inadequate respon…
Patients with ulcerative colitis who failed other treatments achieved remission in a new trial using subcutaneous guselkumab injections.
Guselkumab Shows Improvement in Inverse Psoriasis in Single Case Report
Can a psoriasis drug help with a rare, hard-to-treat skin condition?
A case report and literature review describes a 48-year-old male with inverse psoriasis who showed marked improvement in cutaneous lesions a…
A single patient with hard-to-treat inverse psoriasis found marked relief in itching and skin lesions after just three injections of a newer…
Guselkumab Shows Promise in Crohn's Disease: Phase 3 Study Results
Can a new treatment help people with Crohn's disease feel better and stay better?
The Phase 2/3 study evaluates guselkumab's efficacy and safety in Crohn's disease. Primary outcomes include changes in CDAI and clinical rem…
A new Crohn's treatment study with 1,409 participants aims to help people feel better and stay better for up to 48 weeks.